The ocular surface in glaucoma

Cornea

Volumn 28, Issue SUPPL. 1, 2009, Pages

  Baudouin, Christophe ^a,b  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b INSTITUT DE LA VISION   (France)

Author keywords

Antiglaucoma agents; Benzalkonium chloride; Ocular surface; Preservatives

Indexed keywords

ANTIGLAUCOMA AGENT; BENZALKONIUM CHLORIDE; DRUG PRESERVATIVE; EYE DROPS; TIMOLOL;

BLURRED VISION; BURNING SENSATION; CATARACT; CONFERENCE PAPER; CONJUNCTIVA EPITHELIUM; CORNEA EPITHELIUM; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRY EYE; EPIPHORA; FILTERING OPERATION; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA EDEMA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 76449093179     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181ae8402     Document Type: Conference Paper

References (47)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
2. Lindblom B, Nordmann JP, Sellem E, et al. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand. 2006;84: 74-83.
3. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418-423. (Pubitemid 34293291)
4. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341-349.
5. Chawla A, McGalliard JN, Batterbury M. Use of eye drops in glaucoma: how can we help to reduce non-compliance? Acta Ophthalmol Scand. 2007;85:464.
6. Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008;246:1593-1601.
7. Smith JA, Albeitz J, Begley C, et al. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Workshop. (2007). Ocul Surf. 2007;5:93-107. (Pubitemid 351902652)
8. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350-355.
9. United States Pharmacopeia-National Formulary (USP-NF). Rockville, MD: USP; 2005.
10. Baudouin C. Allergic reaction to topical eye drops. Curr Opin Allergy Clin Immunol. 2005;5:459-463.
11. Wilson WS, Duncan AJ, Jay JL. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol. 1975;59:667-669.
12. Pisella PJ, Fillacier K, Elena PP, et al. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res. 2000;32:3-8.
13. Chou A, Hori S, Takase M. Ocular toxicity of beta-blockers and benzalkonium chloride in pigmented rabbits: electrophysiological and morphological studies. Jpn J Ophthalmol. 1985;29:13-23.
14. Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998;17:419-425.
15. Furrer P, Berger J, Mayer JM, et al. A comparative study of the ocular tolerance of 3 timolol-based preparations: the influence of preservatives on ocular tolerance. J Fr Ophtalmol. 2001;24:13-19.
16. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004; 23:490-496.
17. De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40:619-630.
18. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45: 1360-1368.
19. Samples JR, Binder PS, Nayak S. The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp Eye Res. 1989;49:1-12.
20. Hamard P, Debbasch C, Blondin C, et al. Human trabecular cells and apoptosis: in vitro evaluation of the effect of betaxolol with or without preservative. J Fr Ophtalmol. 2002;25:777-784.
21. Hamard P, Blondin C, Debbasch C, et al. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol. 2003;241: 1037-1043.
22. Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol. 2003;121: 835-839.
23. Kuppens EV, de Jong CA, Stolwijk TR, et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol. 1995;79:339-342.
24. Yalvacx IS, Gedikoǧlu G, Karagöz Y, et al. Effects of antiglaucoma drugs on the ocular surface. Acta Ophthalmol Scand. 1995;73:246-248.
25. Nuzzi R, Finazzo C, Cerruti A. Adverse effects of topical antiglaucomatous medications on the conjunctiva and lachrymal response. Int Ophthalmol. 1998;22:31-35.
26. de Jong C, Stolwijk T, Kuppens E, et al. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994;232: 221-224. (Pubitemid 24127409)
27. Levrat F, Pisella PJ, Baudouin C. Clinical tolerance of antiglaucoma eye drops with and without a preservative. Results of an unpublished survey in Europe. J Fr Ophtalmol. 1999;22:186-191.
28. Detry-Morel M. Side effects of glaucoma medications. Bull Soc Belge Ophtalmol. 2006;299:27-40.
29. Herreras JM, Pastor JC, Calonge M, et al. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992;99:1082-1088.
30. Baudouin C, Hamard P, Liang H, et al. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology. 2004;111:2186-2192.
31. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115:109-115.
32. Sherwood MB, Grierson I, Millar L, et al. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989;96:327-335.
33. Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112:1437-1445. (Pubitemid 24350506)
34. Baudouin C, Pisella PJ, Fallacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106:556-563.
35. Aritürk N, Oge I, Baris S, et al. The effects of antiglaucomatous agents on conjunctiva used for various durations. Int Ophthalmol. 1996;20:57-62.
36. Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446-1454.
37. LavinMJ,Wormald RPL, Migdal CS, et al. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108:1543-1548.
38. Chandrasekaran S, Cumming RG, Rochtchina E, et al. Associations between elevated intraocular pressure and glaucoma, use of glaucoma medications, and 5-year incident cataract: the Blue Mountains Eye Study. Ophthalmology. 2006;113:417-424.
39. Herman DC, Gordon MO, Beiser JA, et al. Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. Am J Ophthalmol. 2006;142:800-810.
40. Miyake K, Ibaraki N, Goto Y, et al. ESCRS Binkhorst Lecture 2002. Pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003; 29:1800-1810.
41. Liesegang TJ. Conjunctival changes associated with glaucoma therapy: implications for the external disease consultant and treatment of glaucoma. Cornea. 1998;17:574-583.
42. Zimmerman TJ, Hahn SR, Gelb L, et al. The effect of hyperemia on openangle glaucoma (OAG) treatment. Paper presented at: Annual Meeting of the European Society of Ophthalmology (SOE); June 9212, 2007; Vienna, Austria. Abstract FP-GLA-036.
43. Nordmann JP, Auzanneau N, Ricard S, et al. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003;1:75.
44. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98-103.
45. Easty DL, Nemeth-Wasmer G, Vounatsos JP, et al. Comparison of a nonpreserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br J Ophthalmol. 2006;90:574-578.
46. Hamacher T, Airaksinen J, Saarela V, et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics study. Acta Ophthalmol Suppl. 2008;242:14-19.
47. Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl. 2008;242:7-13.